IT201700066486A1 - Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche - Google Patents

Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche

Info

Publication number
IT201700066486A1
IT201700066486A1 IT102017000066486A IT201700066486A IT201700066486A1 IT 201700066486 A1 IT201700066486 A1 IT 201700066486A1 IT 102017000066486 A IT102017000066486 A IT 102017000066486A IT 201700066486 A IT201700066486 A IT 201700066486A IT 201700066486 A1 IT201700066486 A1 IT 201700066486A1
Authority
IT
Italy
Prior art keywords
ophthalmological
treatment
neurodegenerative diseases
blood serum
serum
Prior art date
Application number
IT102017000066486A
Other languages
English (en)
Inventor
Emilio C Campos
Piera Versura
Marina Buzzi
Silvia Bisti
Claudio Velati
Original Assignee
Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A
Univ Bologna Alma Mater Studiorum
Univ Degli Studi Dellaquila
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A, Univ Bologna Alma Mater Studiorum, Univ Degli Studi Dellaquila filed Critical Azienda Ospedaliero Univ Policlinico S Orsola Malpighi Bologn A
Priority to IT102017000066486A priority Critical patent/IT201700066486A1/it
Priority to ES18737995T priority patent/ES2947577T3/es
Priority to JP2020519195A priority patent/JP2020523416A/ja
Priority to CN201880053409.6A priority patent/CN110996973A/zh
Priority to EP23156135.8A priority patent/EP4201414A1/en
Priority to CA3066980A priority patent/CA3066980A1/en
Priority to EP18737995.3A priority patent/EP3638259B1/en
Priority to PCT/IB2018/054410 priority patent/WO2018229718A1/en
Priority to US16/622,481 priority patent/US20200138860A1/en
Publication of IT201700066486A1 publication Critical patent/IT201700066486A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
IT102017000066486A 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche IT201700066486A1 (it)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IT102017000066486A IT201700066486A1 (it) 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche
ES18737995T ES2947577T3 (es) 2017-06-15 2018-06-15 Uso de suero sanguíneo en el tratamiento de patologías oftalmológicas neurodegenerativas
JP2020519195A JP2020523416A (ja) 2017-06-15 2018-06-15 神経変性眼科学的病状の治療に使用する血清
CN201880053409.6A CN110996973A (zh) 2017-06-15 2018-06-15 用于治疗神经退行性眼科病变的血清
EP23156135.8A EP4201414A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmologic pathologies
CA3066980A CA3066980A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies
EP18737995.3A EP3638259B1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies
PCT/IB2018/054410 WO2018229718A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies
US16/622,481 US20200138860A1 (en) 2017-06-15 2018-06-15 Blood serum for use in the treatment of neurodegenerative ophthalmological pathologies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000066486A IT201700066486A1 (it) 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche

Publications (1)

Publication Number Publication Date
IT201700066486A1 true IT201700066486A1 (it) 2018-12-15

Family

ID=60138825

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000066486A IT201700066486A1 (it) 2017-06-15 2017-06-15 Siero sanguigno per uso nel trattamento di patologie neurodegenerative oftalmologiche

Country Status (8)

Country Link
US (1) US20200138860A1 (it)
EP (2) EP3638259B1 (it)
JP (1) JP2020523416A (it)
CN (1) CN110996973A (it)
CA (1) CA3066980A1 (it)
ES (1) ES2947577T3 (it)
IT (1) IT201700066486A1 (it)
WO (1) WO2018229718A1 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230210895A1 (en) 2020-08-03 2023-07-06 Sereye Gmbh Composition for treating damaged epithelial surfaces and method of producing same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210185A (en) * 1988-03-18 1993-05-11 Fidia S.P.A. Human nerve growth factor
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6261545B1 (en) * 1996-09-13 2001-07-17 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
US20020102581A1 (en) * 1999-02-19 2002-08-01 Hageman Gregory S. Diagnostics and therapeutics for ocular disorders
CN1668324A (zh) * 2002-05-28 2005-09-14 诺沃塞尔公司 用于胰岛素产生细胞的方法、组合物及生长与分化因子
SG175436A1 (en) * 2009-05-04 2011-12-29 Abbott Res Bv Antibodies against nerve growth factor (ngf) with enhanced in vivo stability

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210185A (en) * 1988-03-18 1993-05-11 Fidia S.P.A. Human nerve growth factor
US20070014760A1 (en) * 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AJAMI A ET AL: "Changes in serum levels of brain derived neurotrophic factor and nerve growth factor-beta in schizophrenic patients before and after treatment.", SCANDINAVIAN JOURNAL OF IMMUNOLOGY JUL 2014, vol. 80, no. 1, July 2014 (2014-07-01), pages 36 - 42, XP002777952, ISSN: 1365-3083 *
KOHSAKA S ET AL: "Increased activity of ornithine decarboxylase in goldfish following optic nerve crush", DEVELOPMENTAL BRAIN RESEARCH, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1, no. 3, 1 June 1981 (1981-06-01), pages 391 - 401, XP024320502, ISSN: 0165-3806, [retrieved on 19810601], DOI: 10.1016/0165-3806(81)90076-6 *
LAKSHMANAN J: "Beta-nerve growth factor measurements in mouse serum.", JOURNAL OF NEUROCHEMISTRY MAR 1986, vol. 46, no. 3, March 1986 (1986-03-01), pages 882 - 891, XP002777951, ISSN: 0022-3042 *
YIP H K ET AL: "Effect of nerve growth factor on regeneration of goldfish optic axons", BRAIN RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 238, no. 2, 29 April 1982 (1982-04-29), pages 329 - 339, XP024259227, ISSN: 0006-8993, [retrieved on 19820429], DOI: 10.1016/0006-8993(82)90108-1 *

Also Published As

Publication number Publication date
EP3638259B1 (en) 2023-02-15
WO2018229718A1 (en) 2018-12-20
ES2947577T3 (es) 2023-08-11
CA3066980A1 (en) 2018-12-20
EP3638259A1 (en) 2020-04-22
JP2020523416A (ja) 2020-08-06
EP4201414A1 (en) 2023-06-28
US20200138860A1 (en) 2020-05-07
CN110996973A (zh) 2020-04-10

Similar Documents

Publication Publication Date Title
SI3377637T1 (sl) Sestavki za uporabo pri postopkih za zdravljenje ran, motenj in bolezni kože
PT4122464T (pt) Combinações terapêuticas para o tratamento de doenças do fígado
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
DK3668513T3 (da) Pyruvatkinase-aktiveringsmidler til anvendelse til behandling af blodsygdomme
IL258459A (en) Therapeutic compositions for treatment of human immunodeficiency virus
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
HUE059050T2 (hu) Aminosavakat tartalmazó készítmények mitokondriális rendellenességgel összefüggõ betegségek kezelésében történõ alkalmazásra
HUE051296T2 (hu) Benzoxazinon-származékok bõrbetegségek kezelésére
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
IL280664A (en) 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases
HUE060322T2 (hu) Belélegezhetõ készítmények tüdõbetegségek kezelése során történõ alkalmazásra
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
EP3311176A4 (en) ROLE OF CITRULLINATION IN THE DIAGNOSIS OF ILLNESSES
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
SMT202400469T1 (it) Ebselen per l'uso nel trattamento della malattia di ménière
IL259381B (en) Mirabegron for the treatment of retinal diseases
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
IL272443A (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
IL269094A (en) Antibodies against eutaxin 2 for use in the treatment of liver diseases